Zucara Therapeutics receives IND clearance for Phase 2 clinical trial of ZT-01

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily use therapeutic to prevent hypoglycemia in people with diabetes, recently announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) application for ZT-01 for the prevention of nocturnal hypoglycemia in patients with Type 1 Diabetes.

Zucara presented at the OBIO® Investment Summit and is part of Workforce Development.

Arsheen Kaur
Previous

MY01 raises CAD 12.5 million for microsensors to aid in physician diagnostics
Next

Nailing it: Innovative project treats toenail fungal infections easily and effectively for seniors